Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

Clinical trial NCT00548405 · COMPLETED

Trial details

NCT number: NCT00548405
Sponsor: Genzyme, a Sanofi Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Sclerosis, Relapsing-Remitting

Start date: 2007-10-01
Primary completion: 2011-09-01
Enrollment: 840

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.